Last update 25 Jun 2025

Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin(University Hospital Erlangen)

Overview

Basic Info

Drug Type
Therapeutic vaccine, Dendritic cell vaccine
Synonyms-
Target
MAGEA3 x melan-A x survivin
Action
modulators
Mechanism
MAGEA3 modulators(Melanoma-associated antigen 3 modulators), melan-A modulators(Melanoma antigen recognized by T-cells 1 modulators), survivin modulators(Baculoviral IAP repeat-containing protein 5 modulators)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Melanoma, Cutaneous MalignantMetastatic melanoma
Originator Organization
University Hospital ErlangenUniversity Hospital Erlangen
Active Organization-
Inactive Organization
University Hospital ErlangenUniversity Hospital Erlangen
License Organization-
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin(University Hospital Erlangen)
NCT00074230
/ CompletedPhase 1/2IIT
Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding for Mage-3, MelanA, and Survivin Antigens
100 Clinical Results associated with Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin(University Hospital Erlangen)
Login to view more data
100 Translational Medicine associated with Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin(University Hospital Erlangen)
Login to view more data
100 Patents (Medical) associated with Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin(University Hospital Erlangen)
Login to view more data
100 Deals associated with Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin(University Hospital Erlangen)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Melanoma, Cutaneous MalignantPhase 2
Germany
University Hospital ErlangenUniversity Hospital Erlangen
01 Jul 2003
Metastatic melanomaPhase 2
Germany
University Hospital ErlangenUniversity Hospital Erlangen
01 Jul 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free